Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Tongrentang Co., Ltd (600085.SS)
CNY25.25
+0.50 (+2.02%)
CN SHH Healthcare Medical - Pharmaceuticals
Address
Tongrentang Building 100084
Beijing, BJ, CN
Beijing, BJ, CN
CEO
Jia Fu Chen
Website
gf.tongrentang.com
IPO
1997-06-27
ISIN CNE000000R69
Description
Beijing Tongrentang Co., Ltd engages in the production and sale of traditional Chinese medicine preparations in China and internationally. The company offers various product dosage forms, such as pills, powders, medicated wines, capsules, oral liquids, and drop pills. Its products are used for cardiovascular, cerebrovascular, gynecology, heat-clearing, respiratory system, nourishing and calming, digestive, pediatrics, wind-dispelling and dampness removing, orthopedics, facial features, dermatological surgery, mental health, and food and beverages applications. The company was founded in 1997 and is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tong Ren Tang Group Co. Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY25.25
+0.50 (+2.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.14
Float Shares
652.16M
Free Float %
47.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.09% | +1.71% | -7.63% | -16.64% | -23.32% | -20.49% | -32.50% | -57.26% | -39.19% | -4.08% | +926.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
25.25
DCF (Unlevered)
42.75
+69.3%
DCF (Levered)
56.37
+123.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.13
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%-7.2% Q1'26: -11.6% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-21.6% Q1'26: -19.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+6.3% Q1'26: +19.1% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+11.0% ★ Q1'26: +15.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+11.7% ★ Q1'26: +16.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.17× ★ Q1'26: 1.22× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.90B
est: 11.13B (-2.1%)
|
12.09B
est: 12.19B (-0.8%)
|
13.38B
est: 13.28B (+0.7%)
|
14.21B
est: 14.50B (-2.0%)
|
13.28B
est: 14.26B (-6.9%)
|
12.83B
est: 12.65B (+1.4%)
|
14.60B
est: 14.94B (-2.3%)
|
15.37B
est: 15.36B (+0.1%)
|
17.86B
est: 17.86B (0.0%)
|
18.60B
est: 18.40B (+1.0%)
|
17.26B
est: 18.48B (-6.6%)
|
18.01B
17.19B – 18.82B
-2.6% YoY
|
19.12B
17.40B – 21.27B
+6.2% YoY
|
19.95B
19.90B – 20.00B
+4.3% YoY
|
| EBITDA |
1.90B
est: 2.00B (-5.0%)
|
2.05B
est: 2.19B (-6.2%)
|
2.33B
est: 2.39B (-2.3%)
|
2.28B
est: 2.60B (-12.3%)
|
2.10B
est: 2.56B (-18.0%)
|
2.25B
est: 2.27B (-1.0%)
|
2.65B
est: 2.68B (-1.4%)
|
2.97B
est: 2.76B (+7.4%)
|
3.30B
est: 3.05B (+8.1%)
|
3.05B
est: 3.14B (-3.1%)
|
2.27B
est: 3.16B (-28.2%)
|
3.08B
2.94B – 3.21B
-2.6% YoY
|
3.27B
2.97B – 3.63B
+6.2% YoY
|
3.41B
3.40B – 3.42B
+4.3% YoY
|
| EBIT |
1.75B
est: 1.76B (-0.6%)
|
1.89B
est: 1.92B (-1.7%)
|
2.15B
est: 2.10B (+2.5%)
|
2.08B
est: 2.29B (-9.1%)
|
1.85B
est: 2.25B (-17.7%)
|
1.91B
est: 2.00B (-4.5%)
|
2.33B
est: 2.36B (-1.4%)
|
2.63B
est: 2.43B (+8.4%)
|
2.95B
est: 2.68B (+10.0%)
|
2.70B
est: 2.76B (-2.3%)
|
1.90B
est: 2.77B (-31.5%)
|
2.70B
2.58B – 2.83B
-2.6% YoY
|
2.87B
2.61B – 3.19B
+6.2% YoY
|
3.00B
2.99B – 3.00B
+4.3% YoY
|
| Net Income |
875.44M
est: 888.11M (-1.4%)
|
933.17M
est: 990.89M (-5.8%)
|
1.02B
est: 1.02B (+0.1%)
|
1.13B
est: 1.10B (+3.0%)
|
985.44M
est: 1.11B (-11.2%)
|
1.03B
est: 999.90M (+3.2%)
|
1.23B
est: 1.29B (-5.1%)
|
1.43B
est: 1.43B (-0.1%)
|
1.67B
est: 1.70B (-2.0%)
|
1.53B
est: 1.74B (-12.2%)
|
1.19B
est: 1.50B (-20.7%)
|
1.36B
1.31B – 1.41B
-9.4% YoY
|
1.57B
1.23B – 1.82B
+15.5% YoY
|
1.62B
1.41B – 1.86B
+3.3% YoY
|
| SGA |
1.23B
est: 1.41B (-13.3%)
|
1.38B
est: 1.55B (-11.2%)
|
1.45B
est: 1.69B (-14.2%)
|
1.61B
est: 1.84B (-12.6%)
|
1.18B
est: 1.81B (-34.7%)
|
1.09B
est: 1.61B (-32.0%)
|
1.22B
est: 1.90B (-35.8%)
|
4.38B
est: 1.95B (+124.4%)
|
1.56B
est: 2.98B (-47.7%)
|
1.76B
est: 3.07B (-42.8%)
|
4.89B
est: 3.08B (+58.8%)
|
3.00B
2.87B – 3.14B
-2.6% YoY
|
3.19B
2.90B – 3.55B
+6.2% YoY
|
3.33B
3.32B – 3.34B
+4.3% YoY
|
| EPS |
0.65
est: 0.65 (+0.4%)
|
0.68
est: 0.72 (-5.9%)
|
0.74
est: 0.74 (-0.1%)
|
0.83
est: 0.80 (+3.3%)
|
1.14
est: 0.81 (+40.8%)
|
1.18
est: 0.73 (+61.9%)
|
1.38
est: 0.94 (+46.4%)
|
1.60
est: 1.04 (+53.6%)
|
1.22
est: 1.24 (-1.8%)
|
1.11
est: 1.26 (-11.8%)
|
0.87
est: 1.09 (-19.9%)
|
0.99
0.96 – 1.02
-8.7% YoY
|
1.09
0.90 – 1.33
+9.6% YoY
|
1.23
1.03 – 1.36
+12.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.77B
OE per share TTM
1.29
Owner's Yield
5.04%
Maintenance CapEx ratio
53.62%
Maint CapEx / Avg PPE
33.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 108 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 0.82% | 651.6K | 0.79% |
| 2 | HSBC MSCI China A UCITS ETF HMCT.L | 0.13% | 181.7K | 0.30% |
| 3 | Xtrackers Harvest CSI 300 China A-Shares ETF ASHR | 0.07% | 989.6K | 0.65% |
| 4 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.07% | 102.5K | 0.35% |
| 5 | Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L | 0.07% | 203.6K | 0.65% |
| 6 | iShares MSCI China A UCITS ETF CNYE.MI | 0.07% | 65.9K | 0.45% |
| 7 | iShares MSCI China A UCITS ETF CNYA.L | 0.07% | 2.00M | 0.40% |
| 8 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.06% | 85.4K | 0.35% |
| 9 | Samsung KODEX China CSI300 ETF 283580.KS | 0.06% | 124.1K | 0.12% |
| 10 | iShares MSCI China A ETF CNYA | 0.06% | 134.6K | 0.60% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
109.9K
Shares Outstanding
1.37B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baoxia Pan | Chief Accountant & Director | — | female |
| Chaohua Zhang | GM & Director | — | female |
| Chunyou Zhang | Executive Vice President | — | male |
| Jiafu Chen | GM & Director | — | male |
| Li Feng | Deputy GM & Board Secretary | — | female |
| Ling Yun Dong | Deputy General Manager | — | male |
| Tian Wang | Deputy General Manager | — | male |
| Zhiqiang Tang | General Counsel | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600085.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
